N-Succinylaspart-1-yl Celecoxib is a Potential Colon-Specific Prodrug of Celecoxib with Improved Therapeutic Properties
Authors:
- Jeongyun KimJKJeongyun Kim
- Hyunjeong KimHKHyunjeong Kim
- Sookjin KangSKSookjin Kang
- Jeong-Hyun YoonJYJeong-Hyun Yoon
- Dae-Duk KimDKDae-Duk Kim
- Young Mi KimYKYoung Mi Kim
- Yunjin JungYunjin Jung
- 1 May 2012
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 101 (5) , 1831-1842
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea (2009-0083533, 521-2008-1-E00193)
- Ministry of Education, Science and Technology
This publication has 25 references indexed in Scilit:
- Chemoprevention of Colorectal CancerDigestion, 2007
- Prevention of Colorectal Cancer in High-Risk Populations: The Increasing Role for Endoscopy and Chemoprevention in FAP and HNPCCDigestion, 2007
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Development of Pulsatile Systems for Targeted Drug Delivery of Celecoxib for Prophylaxis of Colorectal CancerDrug Delivery, 2006
- Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugsChinese Journal of Digestive Diseases, 2006
- Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesJournal of Clinical Investigation, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Selective Inhibition of Cyclooxygenase-2 Enhances Platelet Adhesion in Hamster Arterioles In VivoCirculation, 2004
- Studies on the Development of Colon-targeted Delivery Systems for Celecoxib in the Prevention of Colorectal CancerJournal of Drug Targeting, 2002
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000